Ghrelin Causes Hyperphagia and Obesity in Rats

Alison M. Wren, Caroline J. Small, Caroline R. Abbott, Waljit S. Dhillo, Leighton J. Seal, Mark A. Cohen, Rachel L. Batterham, Shahrad Taheri, Sarah A. Stanley, Mohammad A. Ghatei, Stephen Robert Bloom

Research output: Contribution to journalArticle

899 Citations (Scopus)

Abstract

Ghrelin, a circulating growth hormone-releasing peptide derived from the stomach, stimulates food intake. The lowest systemically effective orexigenic dose of ghrelin was investigated and the resulting plasma ghrelin concentration was compared with that during fasting. The lowest dose of ghrelin that produced a significant stimulation of feeding after intraperitoneal injection was 1 nmol. The plasma ghrelin concentration after intraperitoneal injection of 1 nmol of ghrelin (2.83 ± 0.13 pmol/ml at 60 min postinjection) was not significantly different from that occurring after a 24-h fast (2.79 ± 0.32 pmol/ml). After microinjection into defined hypothalamic sites, ghrelin (30 pmol) stimulated food intake most markedly in the arcuate nucleus (Arc) (0-1 h food intake, 427 ± 43% of control; P < 0.001 vs. control, P < 0.01 vs. all other nuclei), which is potentially accessible to the circulation. After chronic systemic or intracerebroventricular (ICV) administration of ghrelin for 7 days, cumulative food intake was increased (intraperitoneal ghrelin 13.6 ± 3.4 g greater than saline-treated, P < 0.01; ICV ghrelin 19.6 ± 5.5 g greater than saline-treated, P < 0.05). This was associated with excess weight gain (intraperitoneal ghrelin 21.7 ± 1.4 g vs. saline 10.6 ± 1.9 g, P < 0.001; ICV ghrelin 15.3 ± 4.3 g vs. saline 2.2 ± 3.8 g, P < 0.05) and adiposity. These data provide evidence that ghrelin is important in long-term control of food intake and body weight and that circulating ghrelin at fasting concentrations may stimulate food intake.

Original languageEnglish
Pages (from-to)2540-2547
Number of pages8
JournalDiabetes
Volume50
Issue number7-12
Publication statusPublished - Nov 2001
Externally publishedYes

Fingerprint

Hyperphagia
Ghrelin
Obesity
Eating
Intraperitoneal Injections
Fasting
Arcuate Nucleus of Hypothalamus
Adiposity
Microinjections
Weight Gain

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Wren, A. M., Small, C. J., Abbott, C. R., Dhillo, W. S., Seal, L. J., Cohen, M. A., ... Bloom, S. R. (2001). Ghrelin Causes Hyperphagia and Obesity in Rats. Diabetes, 50(7-12), 2540-2547.

Ghrelin Causes Hyperphagia and Obesity in Rats. / Wren, Alison M.; Small, Caroline J.; Abbott, Caroline R.; Dhillo, Waljit S.; Seal, Leighton J.; Cohen, Mark A.; Batterham, Rachel L.; Taheri, Shahrad; Stanley, Sarah A.; Ghatei, Mohammad A.; Bloom, Stephen Robert.

In: Diabetes, Vol. 50, No. 7-12, 11.2001, p. 2540-2547.

Research output: Contribution to journalArticle

Wren, AM, Small, CJ, Abbott, CR, Dhillo, WS, Seal, LJ, Cohen, MA, Batterham, RL, Taheri, S, Stanley, SA, Ghatei, MA & Bloom, SR 2001, 'Ghrelin Causes Hyperphagia and Obesity in Rats', Diabetes, vol. 50, no. 7-12, pp. 2540-2547.
Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA et al. Ghrelin Causes Hyperphagia and Obesity in Rats. Diabetes. 2001 Nov;50(7-12):2540-2547.
Wren, Alison M. ; Small, Caroline J. ; Abbott, Caroline R. ; Dhillo, Waljit S. ; Seal, Leighton J. ; Cohen, Mark A. ; Batterham, Rachel L. ; Taheri, Shahrad ; Stanley, Sarah A. ; Ghatei, Mohammad A. ; Bloom, Stephen Robert. / Ghrelin Causes Hyperphagia and Obesity in Rats. In: Diabetes. 2001 ; Vol. 50, No. 7-12. pp. 2540-2547.
@article{a439e7e863354ef0a3eecc2c9e7b9e82,
title = "Ghrelin Causes Hyperphagia and Obesity in Rats",
abstract = "Ghrelin, a circulating growth hormone-releasing peptide derived from the stomach, stimulates food intake. The lowest systemically effective orexigenic dose of ghrelin was investigated and the resulting plasma ghrelin concentration was compared with that during fasting. The lowest dose of ghrelin that produced a significant stimulation of feeding after intraperitoneal injection was 1 nmol. The plasma ghrelin concentration after intraperitoneal injection of 1 nmol of ghrelin (2.83 ± 0.13 pmol/ml at 60 min postinjection) was not significantly different from that occurring after a 24-h fast (2.79 ± 0.32 pmol/ml). After microinjection into defined hypothalamic sites, ghrelin (30 pmol) stimulated food intake most markedly in the arcuate nucleus (Arc) (0-1 h food intake, 427 ± 43{\%} of control; P < 0.001 vs. control, P < 0.01 vs. all other nuclei), which is potentially accessible to the circulation. After chronic systemic or intracerebroventricular (ICV) administration of ghrelin for 7 days, cumulative food intake was increased (intraperitoneal ghrelin 13.6 ± 3.4 g greater than saline-treated, P < 0.01; ICV ghrelin 19.6 ± 5.5 g greater than saline-treated, P < 0.05). This was associated with excess weight gain (intraperitoneal ghrelin 21.7 ± 1.4 g vs. saline 10.6 ± 1.9 g, P < 0.001; ICV ghrelin 15.3 ± 4.3 g vs. saline 2.2 ± 3.8 g, P < 0.05) and adiposity. These data provide evidence that ghrelin is important in long-term control of food intake and body weight and that circulating ghrelin at fasting concentrations may stimulate food intake.",
author = "Wren, {Alison M.} and Small, {Caroline J.} and Abbott, {Caroline R.} and Dhillo, {Waljit S.} and Seal, {Leighton J.} and Cohen, {Mark A.} and Batterham, {Rachel L.} and Shahrad Taheri and Stanley, {Sarah A.} and Ghatei, {Mohammad A.} and Bloom, {Stephen Robert}",
year = "2001",
month = "11",
language = "English",
volume = "50",
pages = "2540--2547",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "7-12",

}

TY - JOUR

T1 - Ghrelin Causes Hyperphagia and Obesity in Rats

AU - Wren, Alison M.

AU - Small, Caroline J.

AU - Abbott, Caroline R.

AU - Dhillo, Waljit S.

AU - Seal, Leighton J.

AU - Cohen, Mark A.

AU - Batterham, Rachel L.

AU - Taheri, Shahrad

AU - Stanley, Sarah A.

AU - Ghatei, Mohammad A.

AU - Bloom, Stephen Robert

PY - 2001/11

Y1 - 2001/11

N2 - Ghrelin, a circulating growth hormone-releasing peptide derived from the stomach, stimulates food intake. The lowest systemically effective orexigenic dose of ghrelin was investigated and the resulting plasma ghrelin concentration was compared with that during fasting. The lowest dose of ghrelin that produced a significant stimulation of feeding after intraperitoneal injection was 1 nmol. The plasma ghrelin concentration after intraperitoneal injection of 1 nmol of ghrelin (2.83 ± 0.13 pmol/ml at 60 min postinjection) was not significantly different from that occurring after a 24-h fast (2.79 ± 0.32 pmol/ml). After microinjection into defined hypothalamic sites, ghrelin (30 pmol) stimulated food intake most markedly in the arcuate nucleus (Arc) (0-1 h food intake, 427 ± 43% of control; P < 0.001 vs. control, P < 0.01 vs. all other nuclei), which is potentially accessible to the circulation. After chronic systemic or intracerebroventricular (ICV) administration of ghrelin for 7 days, cumulative food intake was increased (intraperitoneal ghrelin 13.6 ± 3.4 g greater than saline-treated, P < 0.01; ICV ghrelin 19.6 ± 5.5 g greater than saline-treated, P < 0.05). This was associated with excess weight gain (intraperitoneal ghrelin 21.7 ± 1.4 g vs. saline 10.6 ± 1.9 g, P < 0.001; ICV ghrelin 15.3 ± 4.3 g vs. saline 2.2 ± 3.8 g, P < 0.05) and adiposity. These data provide evidence that ghrelin is important in long-term control of food intake and body weight and that circulating ghrelin at fasting concentrations may stimulate food intake.

AB - Ghrelin, a circulating growth hormone-releasing peptide derived from the stomach, stimulates food intake. The lowest systemically effective orexigenic dose of ghrelin was investigated and the resulting plasma ghrelin concentration was compared with that during fasting. The lowest dose of ghrelin that produced a significant stimulation of feeding after intraperitoneal injection was 1 nmol. The plasma ghrelin concentration after intraperitoneal injection of 1 nmol of ghrelin (2.83 ± 0.13 pmol/ml at 60 min postinjection) was not significantly different from that occurring after a 24-h fast (2.79 ± 0.32 pmol/ml). After microinjection into defined hypothalamic sites, ghrelin (30 pmol) stimulated food intake most markedly in the arcuate nucleus (Arc) (0-1 h food intake, 427 ± 43% of control; P < 0.001 vs. control, P < 0.01 vs. all other nuclei), which is potentially accessible to the circulation. After chronic systemic or intracerebroventricular (ICV) administration of ghrelin for 7 days, cumulative food intake was increased (intraperitoneal ghrelin 13.6 ± 3.4 g greater than saline-treated, P < 0.01; ICV ghrelin 19.6 ± 5.5 g greater than saline-treated, P < 0.05). This was associated with excess weight gain (intraperitoneal ghrelin 21.7 ± 1.4 g vs. saline 10.6 ± 1.9 g, P < 0.001; ICV ghrelin 15.3 ± 4.3 g vs. saline 2.2 ± 3.8 g, P < 0.05) and adiposity. These data provide evidence that ghrelin is important in long-term control of food intake and body weight and that circulating ghrelin at fasting concentrations may stimulate food intake.

UR - http://www.scopus.com/inward/record.url?scp=0035514596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035514596&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 2540

EP - 2547

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 7-12

ER -